(VIANEWS) – Lincoln National Corporation (LNC), Golden Bull Limited (BTBT), Virtu Financial (VIRT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Lincoln National Corporation (LNC)
138.3% sales growth and 25.19% return on equity
Lincoln National Corporation, through its subsidiaries, operates multiple insurance and retirement businesses in the United States. It operates through four segments: Annuities, Retirement Plan Services, Life Insurance, and Group Protection. The Annuities segment offers variable, fixed, and indexed variable annuities. The Retirement Plan Services segment provides employers with retirement plan products and services primarily in the defined contribution retirement plan marketplace. This segment offers individual and group variable annuities, group fixed annuities, and mutual fund-based programs; and a range of plan services, including plan recordkeeping, compliance testing, participant education, and trust and custodial services. The Life Insurance segment provides life insurance products, including term insurance, such as single and survivorship versions of universal life insurance; variable universal life insurance; indexed universal life insurance products; and critical illness and long-term care riders. The Group Protection segment offers group non-medical insurance products comprising short and long-term disability, statutory disability and paid family medical leave administration and absence management services, term life, dental, vision and accident, and critical illness benefits and services to the employer marketplace through various forms of employee-paid and employer-paid plans. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries. Lincoln National Corporation was founded in 1905 and is headquartered in Radnor, Pennsylvania.
Earnings Per Share
As for profitability, Lincoln National Corporation has a trailing twelve months EPS of $9.52.
PE Ratio
Lincoln National Corporation has a trailing twelve months price to earnings ratio of 3.09. Meaning, the purchaser of the share is investing $3.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.19%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Oct 10, 2024, the estimated forward annual dividend rate is 1.8 and the estimated forward annual dividend yield is 6.14%.
2. Golden Bull Limited (BTBT)
137.3% sales growth and 14.95% return on equity
Bit Digital, Inc., together with its subsidiaries, engages in the bitcoin mining business. It is also involved in the treasury management activities; and digital asset staking and digital asset mining businesses, as well as ethereum staking activities. The company was formerly known as Golden Bull Limited and changed its name to Bit Digital, Inc. in September 2020. Bit Digital, Inc. was founded in 2015 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Golden Bull Limited has a trailing twelve months EPS of $0.21.
PE Ratio
Golden Bull Limited has a trailing twelve months price to earnings ratio of 12.71. Meaning, the purchaser of the share is investing $12.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.95%.
Volume
Today’s last reported volume for Golden Bull Limited is 6046440 which is 48.72% below its average volume of 11792200.
3. Virtu Financial (VIRT)
35.1% sales growth and 24.4% return on equity
Virtu Financial, Inc., together with its subsidiaries, provides market making and liquidity services through its proprietary, multi-asset, and multi-currency technology platform to the financial markets worldwide. The company's Market Making segment principally consists of market making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Its Execution Services segment comprises agency-based trading and trading venues, which offer execution services in equities, ETFs, futures, fixed income, currencies, and commodities to institutions, banks, and broker dealers. Virtu Financial, Inc. was founded in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Virtu Financial has a trailing twelve months EPS of $1.99.
PE Ratio
Virtu Financial has a trailing twelve months price to earnings ratio of 15.62. Meaning, the purchaser of the share is investing $15.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.4%.
Yearly Top and Bottom Value
Virtu Financial’s stock is valued at $31.08 at 06:22 EST, below its 52-week high of $31.85 and way higher than its 52-week low of $16.02.
Volume
Today’s last reported volume for Virtu Financial is 120749 which is 92.17% below its average volume of 1543140.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 30, 2024, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 3.05%.
4. Neurocrine Biosciences (NBIX)
20.8% sales growth and 15.55% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $3.32.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 38.27. Meaning, the purchaser of the share is investing $38.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.55%.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $127.06 at 06:22 EST, way below its 52-week high of $157.98 and way above its 52-week low of $103.63.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1236880 which is 43.96% above its average volume of 859176.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.4%, now sitting on 2.12B for the twelve trailing months.
5. Radian Group (RDN)
12.5% sales growth and 13.95% return on equity
Radian Group Inc., together with its subsidiaries, engages in the mortgage and real estate services business in the United States. It operates through two segments, Mortgage Insurance and Homegenius segments. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans; and other credit risk management solutions, including contract underwriting. The Homegenius segment offers title services, including a suite of insurance and non-insurance titles; tax and title data, centralized recording, document retrieval, and default curative title services; deed and property reports; closing and settlement services; mortgage underwriting and processing; escrow; appraisal management; and real estate brokerage. This segment also provides real estate valuation products and services; asset management services for managing real estate owned properties, which includes a web-based workflow solution; and a suite of real estate technology products and services to facilitate real estate transactions, such as proprietary platforms as a service solution. It serves mortgage originators, such as mortgage bankers, commercial banks, savings institutions, credit unions, and community banks; and consumers, mortgage lenders, mortgage and real estate investors, government-sponsored enterprises, real estate brokers and agents, and corporations for their employees. The company was formerly known as CMAC Investment Corp. and changed its name to Radian Group Inc. in June 1999. Radian Group Inc. was founded in 1977 and is headquartered in Wayne, Pennsylvania.
Earnings Per Share
As for profitability, Radian Group has a trailing twelve months EPS of $3.84.
PE Ratio
Radian Group has a trailing twelve months price to earnings ratio of 9.15. Meaning, the purchaser of the share is investing $9.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.95%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 12.5% and a negative 6.2%, respectively.
Volume
Today’s last reported volume for Radian Group is 620002 which is 27.03% below its average volume of 849700.
